Drugs / Digibind
Digibind
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00550576 | Oct 2007 → Feb 2009 | bipolar disorder | Rambam Health Care Campus | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00852787 | Apr 2009 → May 2012 | hypertensive disorder | National Institute on Aging (NIA) | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00158743 Comparator | Feb 2004 → Dec 2007 | preeclampsia | BTG International Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Digibind | “Digibind (Glaxo Smith Kline) is a commercially available FAB fragment, antidigoxin antibody approved for the treatment of digoxin intoxication.” NCT00158743 ↗ |
| Known as | Digoxin Antibodies-Fab | “Intravenous Digibind (Digoxin Antibodies-Fab) is delivered only once in 30-45 minutes to patients after receiving the informed concent.” NCT00550576 ↗ |
| Known as | Digoxin immune fab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00852787 ↗ |
| Modality | Protein / enzyme biologic | “a commercially available FAB fragment, antidigoxin antibody” NCT00158743 ↗ |
| Route | Intravenous | “intravenous administered” NCT00158743 ↗ |